Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥55.00 - ¥179.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)548.36K
Market Cap
¥4.33B
Enterprise Value¥5.70B
Total Cash (Recent Filing)¥2.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Jan 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.05
Shares Outstanding77,358,400
10 Day Avg. Volume525,420
30 Day Avg. Volume548,363
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.83
Price to Sales (P/S)0.00
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt reduces mandatory interest and refinancing obligations, preserving financial flexibility while the company funds oncology research. This structure can help management direct available capital toward development priorities and limit leverage-related downside during periods of operating losses.
Oncology SpecializationA dedicated focus on novel oncology therapeutics gives the company a clearly defined research domain and supports concentration of its scientific resources. If candidates advance successfully, this specialized pipeline can create opportunities for licensing, co-development, or eventual product commercialization.
Multiple Monetization RoutesThe business model offers several potential paths to monetize successful drug development, including partnership payments, future royalties, and product revenue. These routes could provide substantial operating leverage if candidates achieve development or commercial milestones, although realization depends on clinical progress.
Bears Say
Irregular Revenue BaseRepeated periods of zero revenue indicate that the current operation lacks a dependable commercial income stream. This makes financial performance highly dependent on irregular transactions or development outcomes and reduces the company’s ability to fund ongoing oncology research from recurring internal revenue.
Persistent Operating LossesLarge recurring operating losses show that the existing cost base is not supported by current revenue generation. Continued losses can erode financial resources and place greater importance on successful development milestones, partnerships, or future financing to sustain the pipeline over the next several quarters.
Heavy Cash Burn And Equity ErosionRecent cash burn combined with a materially smaller equity base signals weakening financial capacity despite the absence of debt. If negative cash generation persists, the company may have less flexibility to advance candidates internally and may need additional funding or partnership proceeds.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥55.00 and its highest was ¥179.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥4.33B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jan 20, 2027 which is in 93 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Oct 15, 2026. The company reported -¥10.79 earnings per share for the quarter.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 77,358,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥10.79 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―